Prognostic biomarkers for survival in mucosal melanoma

IF 3.9 3区 医学 Q2 CELL BIOLOGY Pigment Cell & Melanoma Research Pub Date : 2023-06-30 DOI:10.1111/pcmr.13104
Julia C. Thierauf, Stefan T. Kaluziak, Elizabeth Codd, Stacy N. Dybel, Soma Jobbagy, Rashi Purohit, Alex A. Farahani, Aikaterini Dedeilia, Vivek Naranbhai, Mai P. Hoang, Adam S. Fisch, Lauren Ritterhouse, Genevieve M. Boland, Jochen K. Lennerz, A. John Iafrate
{"title":"Prognostic biomarkers for survival in mucosal melanoma","authors":"Julia C. Thierauf,&nbsp;Stefan T. Kaluziak,&nbsp;Elizabeth Codd,&nbsp;Stacy N. Dybel,&nbsp;Soma Jobbagy,&nbsp;Rashi Purohit,&nbsp;Alex A. Farahani,&nbsp;Aikaterini Dedeilia,&nbsp;Vivek Naranbhai,&nbsp;Mai P. Hoang,&nbsp;Adam S. Fisch,&nbsp;Lauren Ritterhouse,&nbsp;Genevieve M. Boland,&nbsp;Jochen K. Lennerz,&nbsp;A. John Iafrate","doi":"10.1111/pcmr.13104","DOIUrl":null,"url":null,"abstract":"<p>Mucosal melanoma (MM) is a rare subtype of melanoma with an aggressive clinical course. In cutaneous melanoma (CM), the absence of pigmentation and presence of NRAS/KRAS mutations are biomarkers indicating an aggressive clinical course with shorter overall survival. Similar data for MM are missing. We present the real-world outcome data in a cohort of genotyped MM patients and assessed the prognostic relevance of pigmentation- and NRAS/KRAS mutation status. We correlated pathological reports and clinical data with overall survival of patients with MM. Furthermore, we performed clinically integrated molecular genotyping and analyzed real world treatment regimens for covariates associated with clinical outcome. We identified 39 patients with available clinical and molecular data. Patients with amelanotic MM had a significantly shorter overall survival (<i>p</i> = .003). In addition, the presence of a NRAS or KRAS mutation was significantly associated with poor overall survival (NRAS or KRAS <i>p</i> = .024). Currently, it is unknown if the same prognostic relevance for the lack of pigmentation and RAS mutations in CM, exists in MM. Here we analyzed a cohort of MM for outcome measures and determined that two known prognostic biomarkers for CM are in fact novel prognosticators for MM.</p>","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.13104","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pigment Cell & Melanoma Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/pcmr.13104","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Mucosal melanoma (MM) is a rare subtype of melanoma with an aggressive clinical course. In cutaneous melanoma (CM), the absence of pigmentation and presence of NRAS/KRAS mutations are biomarkers indicating an aggressive clinical course with shorter overall survival. Similar data for MM are missing. We present the real-world outcome data in a cohort of genotyped MM patients and assessed the prognostic relevance of pigmentation- and NRAS/KRAS mutation status. We correlated pathological reports and clinical data with overall survival of patients with MM. Furthermore, we performed clinically integrated molecular genotyping and analyzed real world treatment regimens for covariates associated with clinical outcome. We identified 39 patients with available clinical and molecular data. Patients with amelanotic MM had a significantly shorter overall survival (p = .003). In addition, the presence of a NRAS or KRAS mutation was significantly associated with poor overall survival (NRAS or KRAS p = .024). Currently, it is unknown if the same prognostic relevance for the lack of pigmentation and RAS mutations in CM, exists in MM. Here we analyzed a cohort of MM for outcome measures and determined that two known prognostic biomarkers for CM are in fact novel prognosticators for MM.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
粘膜黑色素瘤的预后生物标志物
黏膜黑色素瘤(MM)是一种罕见的黑色素瘤亚型,具有侵袭性的临床病程。在皮肤黑色素瘤(CM)中,色素沉着的缺失和NRAS/KRAS突变的存在是表明侵袭性临床病程和较短总生存期的生物标志物。MM的类似数据缺失。我们提供了一组基因型MM患者的真实结果数据,并评估了色素沉着和NRAS/KRAS突变状态与预后的相关性。我们将病理报告和临床数据与MM患者的总生存期联系起来。此外,我们进行了临床整合的分子基因分型,并分析了与临床结果相关的实际治疗方案。我们确定了39例具有可用临床和分子数据的患者。无色性MM患者的总生存期明显缩短(p = 0.003)。此外,NRAS或KRAS突变的存在与较差的总生存率显著相关(NRAS或KRAS p = 0.024)。目前,尚不清楚CM中缺乏色素沉着和RAS突变是否与MM存在相同的预后相关性。在这里,我们分析了MM队列的结果测量,并确定两个已知的CM预后生物标志物实际上是MM的新预后指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pigment Cell & Melanoma Research
Pigment Cell & Melanoma Research 医学-皮肤病学
CiteScore
8.90
自引率
2.30%
发文量
54
审稿时长
6-12 weeks
期刊介绍: Pigment Cell & Melanoma Researchpublishes manuscripts on all aspects of pigment cells including development, cell and molecular biology, genetics, diseases of pigment cells including melanoma. Papers that provide insights into the causes and progression of melanoma including the process of metastasis and invasion, proliferation, senescence, apoptosis or gene regulation are especially welcome, as are papers that use the melanocyte system to answer questions of general biological relevance. Papers that are purely descriptive or make only minor advances to our knowledge of pigment cells or melanoma in particular are not suitable for this journal. Keywords Pigment Cell & Melanoma Research, cell biology, melatonin, biochemistry, chemistry, comparative biology, dermatology, developmental biology, genetics, hormones, intracellular signalling, melanoma, molecular biology, ocular and extracutaneous melanin, pharmacology, photobiology, physics, pigmentary disorders
期刊最新文献
The Lipid Droplet Protein DHRS3 Is a Regulator of Melanoma Cell State. UVA Irradiation Promotes Melanoma Cell Proliferation Mediated by OPN3 Independently of ROS Production. Issue Information Bay 11-7082, an NF-κB Inhibitor, Prevents Post-Inflammatory Hyperpigmentation Through Inhibition of Inflammation and Melanogenesis. Low-Dose Baricitinib Plus Narrow-Band Ultraviolet B for the Treatment of Progressive Non-Segmental Vitiligo: A Prospective, Controlled, Open-Label Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1